Sativex Could Be A Major Growth Catalyst For GW Pharmaceuticals PLC – ADR (NASDAQ:GWPH)

Boston, MA, 03/31/2014 (medicalmarijuanareporter.com) – GW Pharmaceuticals PLC – ADR (NASDAQ:GWPH) is engaged in the development of innovative therapies based on its proprietary cannabinoid platform. It’s lead molecule Sativex, an extract from marijuana has approval for Multiple Sclerosis and is presently undergoing clinical trials for Cancer Pain (Phase III) and Neuropathic Pain (Phase II). The other drug in its pipeline Epidiolex is being investigated for the possible uses for the treatment of epilepsy. The company is focused on the treatment of pain through cannabis extracts. After the company completed its IPO at a price of $8, analysts initially set price targets in the $ 20 range but these have subsequently been raised to a low of $ 40 and a high of$ 97. The share currently trades at $60.26.

GW Pharmaceuticals PLC – ADR (NASDAQ:GWPH) recently provided a review of its pipeline and its products based on cannabinoid cannabidivarin (HempV) which is derived from the cannabis plant. Among other things, HempV has displayed the ability to treat epilepsy with less severe side effects than the currently approved treatments. The United Kingdom has approved a patent using the drug in epilepsy. The other candidate, Epidiolex, contains cannabidiol (Hemp) as its principal ingredient and has been approved for orphan drug designation from the FDA in the treatment of two infantile nt epilepsy disorders.

Sativex is in its early stages of commercialization which has been initiated only in 11 countries outside the U.S. and should be launched commercially in 2014 in the 11 more countries where regulatory approval has already been given. Approval in the U.S. would make GW Pharmaceuticals PLC – ADR (NASDAQ:GWPH) a prime target for an acquisition. The potential target market for treatments such as epilepsy and cancer pain could well run into the millions of patients globally. This potential is all the more exciting when you consider the relative lack of side effects compared to other treatments. This is a stock with enormous growth potential.